Merck KGaA Acquires Rights For Colorectal Cancer Therapy UFT From Taiho
This article was originally published in The Pink Sheet Daily
Executive Summary
Germany-based Merck says it has not decided whether it will seek FDA approval for the uracil/tegafur combination; FDA deemed UFT “not approvable” for advanced colorectal cancer in 2001, when Bristol held rights to the agent.